Answer
Rifampicin strongly induces CYP3A and the P-gp efflux transporter, markedly reducing eliglustat tartrate exposure, so concomitant use is not recommended in CYP2D6 intermediate, extensive or poor metabolisers.
Sources for this answer
- Cerdelga 84 mg capsules, hardSANOFI · emc · SmPC §4.5 Interaction with other medicinal products · Version 13Document updated
Sources checked